We are a leader in the field of neuronal nicotinic receptor (NNR) chemistry and biology. Our product candidates are designed to selectively act on NNRs, an underexploited class of molecular targets, to meet unmet medical needs across a broad spectrum of therapeutic indications with large market potential, including:

Alzheimer's disease Cognitive dysfunction in schizophrenia Depression/Anxiety Pain Smoking cessation Obesity Schizophrenia  Addiction Parkinson's disease Inflammation

Neuronal nicotinic receptors (NNRs)